JP5113979B2 - 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 - Google Patents

複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 Download PDF

Info

Publication number
JP5113979B2
JP5113979B2 JP2003572923A JP2003572923A JP5113979B2 JP 5113979 B2 JP5113979 B2 JP 5113979B2 JP 2003572923 A JP2003572923 A JP 2003572923A JP 2003572923 A JP2003572923 A JP 2003572923A JP 5113979 B2 JP5113979 B2 JP 5113979B2
Authority
JP
Japan
Prior art keywords
compound
sarm
androgen receptor
another embodiment
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003572923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526741A (ja
JP2005526741A5 (https=
Inventor
ダルトン、ジェームズ・ティー
ミラー、デュアン・ディー
ステイナー、ミッチェル・エス
ベベルカ、カレン・エイ
チェン、ジユン
ファン、ドンジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Priority claimed from PCT/US2003/003123 external-priority patent/WO2003074449A2/en
Publication of JP2005526741A publication Critical patent/JP2005526741A/ja
Publication of JP2005526741A5 publication Critical patent/JP2005526741A5/ja
Application granted granted Critical
Publication of JP5113979B2 publication Critical patent/JP5113979B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
JP2003572923A 2002-02-28 2003-02-24 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法 Expired - Fee Related JP5113979B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45373602P 2002-02-28 2002-02-28
US60/453,736 2002-02-28
US42338102P 2002-11-04 2002-11-04
US60/423,381 2002-11-04
PCT/US2003/003123 WO2003074449A2 (en) 2002-02-28 2003-02-24 Multi-substitued selective androgen receptor modulators and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010110335A Division JP2010180245A (ja) 2002-02-28 2010-05-12 選択的アンドロゲンレセプタ修飾因子の結合方法及び使用方法

Publications (3)

Publication Number Publication Date
JP2005526741A JP2005526741A (ja) 2005-09-08
JP2005526741A5 JP2005526741A5 (https=) 2006-04-13
JP5113979B2 true JP5113979B2 (ja) 2013-01-09

Family

ID=33422848

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003572923A Expired - Fee Related JP5113979B2 (ja) 2002-02-28 2003-02-24 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法
JP2010110335A Pending JP2010180245A (ja) 2002-02-28 2010-05-12 選択的アンドロゲンレセプタ修飾因子の結合方法及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010110335A Pending JP2010180245A (ja) 2002-02-28 2010-05-12 選択的アンドロゲンレセプタ修飾因子の結合方法及び使用方法

Country Status (7)

Country Link
US (1) US7705182B2 (https=)
EP (1) EP1487458B1 (https=)
JP (2) JP5113979B2 (https=)
KR (2) KR20040101251A (https=)
CN (1) CN1700923B (https=)
AT (1) ATE533494T1 (https=)
ES (1) ES2528764T3 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
HRP20180500T1 (hr) * 2007-09-11 2018-06-01 Gtx, Inc. Kristalni polimorf selektivnih modulatora androgena (r) ili (s)-n-(4-cijano-3-(trifluorometil)fenil)-3-(4-cijanofenoksi)-2-hidroksi-2-metilpropanamida
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
CN103002737A (zh) * 2010-01-11 2013-03-27 Gtx公司 治疗睑板腺功能障碍的方法
WO2012020806A1 (ja) 2010-08-11 2012-02-16 旭硝子株式会社 撥水撥油剤組成物および物品
US8395552B2 (en) 2010-11-23 2013-03-12 Metamagnetics, Inc. Antenna module having reduced size, high gain, and increased power efficiency
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
MX2017004819A (es) * 2014-10-16 2018-06-12 Gtx Inc Metodos de tratamiento de transtornos urológicos usando sarm.
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
WO2019001171A1 (zh) * 2017-06-27 2019-01-03 维眸生物科技上海有限公司 一种含磷化合物及其制备和应用
CN109134533B (zh) * 2017-06-27 2020-08-11 维眸生物科技（上海）有限公司 一种含磷化合物及其制备和应用
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
JP2023544201A (ja) 2020-10-08 2023-10-20 ターグイミューン セラピューティクス アクチエンゲゼルシャフト がんを処置するための免疫療法
CA3237153A1 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
EP4615511A1 (en) 2022-11-07 2025-09-17 TargImmune Therapeutics AG Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
KR20250105420A (ko) 2022-11-07 2025-07-08 타르그이뮨 테라퓨틱스 아게 핵산 및 폴리에틸렌이민 및 폴리에틸렌 글리콜을 포함하는 표적화된 컨쥬게이트의 다중복합체
KR20250106292A (ko) 2022-11-07 2025-07-09 타르그이뮨 테라퓨틱스 아게 폴리에틸렌이민 및 폴리에틸렌 글리콜을 포함하는 psma 표적화 선형 컨쥬게이트 및 이들을 포함하는 다중복합체
EP4619000A1 (en) * 2022-11-17 2025-09-24 Vivavision Biotech, Inc. Phosphorus-containing compounds for treating inflammatory bowel diesease
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB136001A (en) 1919-01-11 1919-12-11 Frank Harrison An Adjustable Angle, and Surface-marking Plate.
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4633025A (en) 1985-04-15 1986-12-30 Miles Laboratories, Inc. Method for preparing (+)R-2-methyl-hexane-1,2-diol
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
EP1043325B1 (en) 1994-12-22 2004-06-16 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
JP2000513362A (ja) 1996-06-27 2000-10-10 リガンド・ファーマスーティカルス・インコーポレーテッド アンドロゲン受容体モジュレーター化合物及び方法
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6160011A (en) * 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
RU2234920C2 (ru) 1999-06-11 2004-08-27 Уотсон Фармасьютикалс, Инк. Введение непероральным путем андрогенных стероидов женщинам
AU775928B2 (en) 1999-10-14 2004-08-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
PL354620A1 (en) 1999-10-19 2004-02-09 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
CN1413188A (zh) 1999-10-27 2003-04-23 诺贝克斯公司 基本纯的比卡鲁胺合成中中间体的拆分
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
BR0111298A (pt) 2000-06-28 2005-05-10 Bristol Myers Squibb Co Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
RU2003102390A (ru) 2000-06-28 2004-05-27 Бристол-Маерс Сквибб Компани (Us) Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения
EP1401801B1 (en) * 2000-08-24 2006-11-02 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7547728B2 (en) 2001-12-06 2009-06-16 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Also Published As

Publication number Publication date
CN1700923B (zh) 2011-06-15
EP1487458A2 (en) 2004-12-22
KR101088352B1 (ko) 2011-11-30
US7705182B2 (en) 2010-04-27
ATE533494T1 (de) 2011-12-15
US20060183931A1 (en) 2006-08-17
CN1700923A (zh) 2005-11-23
JP2010180245A (ja) 2010-08-19
EP1487458B1 (en) 2011-11-16
ES2528764T3 (es) 2015-02-12
JP2005526741A (ja) 2005-09-08
EP1487458A4 (en) 2006-07-26
KR20100103662A (ko) 2010-09-27
KR20040101251A (ko) 2004-12-02

Similar Documents

Publication Publication Date Title
JP5113979B2 (ja) 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法
CN100537520C (zh) N-桥连选择性雄激素受体调节剂及其使用方法
JP4764719B2 (ja) ハロゲン化選択的アンドロゲン受容体調節剤及びその使用方法
JP2006506318A (ja) ハロアセトアミド若しくはアジ化物置換化合物及びその使用方法
JP2006518328A (ja) 複素環選択的アンドロゲン受容体調節剤及びその使用方法
JP2006506369A (ja) メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
JP2005519111A (ja) 不可逆型選択的アンドロゲンレセプタ修飾因子及びその使用方法
MXPA04009460A (es) Moduladores receptores de androgeno selectivo multi-sustituidos y metodos de uso de los mismos.
JP2006516286A (ja) Ｓａｒｍによる女性のアンドロゲン減少に関連する病気の治療
KR20040105208A (ko) 할로아세트아미드 및 아지드 치환 화합물 및 그의 용도
EP2266577A1 (en) Multi-substitued selective androgen receptor modulators and methods of use therof
HK1152492A (en) Multi-substitued selective androgen receptor modulators and methods of use therof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100618

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100623

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120209

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20120724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121015

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151019

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5113979

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees